ReviewMedical oncology (Northwood, London, England)2025
Precision oncology: transforming cancer care through personalized medicine.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.MedComm · 2026Review
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Explainable EEG-based machine learning for early diagnosis of Alzheimer's disease and frontotemporal dementia.Scientific reports · 2026Article
- Benzimidazole derivatives as dual EGFR and BRAFRSC advances · 2026Article
- A Review of 3D-Printed Medical Devices for Cancer Radiation Therapy.Bioengineering (Basel, Switzerland) · 2026Review
- Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.Frontiers in oncology · 2026Review
- Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.Cancer management and research · 2026Review
- Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.International journal of nanomedicine · 2026Review
- Costs of breast cancer care by stage and HER-2 Status: a population-based study.Frontiers in health services · 2026Article
- GPCR signaling systems facilitate precision interventions for multi-oncology therapy.Frontiers in systems biology · 2026Review
- Immunotherapy resistance and strategies in malignant pleural mesothelioma.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Apoptosis, Oxidative Stress, and Cell Cycle Disruption: Antitumor Effects of a Novel Palladium(II) Complexes.Journal of medicinal chemistry · 2025Article
- Review
- Plant Antimicrobial Oligopeptides with Anticancer Properties as a Source of Biologically Active Peptides-AnInternational journal of molecular sciences · 2025Article
- Review
- Nutritional strategies in supporting immune checkpoint inhibitor, PI3K inhibitor, and tyrosine kinase inhibitor cancer therapies.Frontiers in nutrition · 2025Review
- Targeted therapy and biomarker-guided applications of ecofriendly silver nanoparticles in precision oncology.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine has revolutionized cancer treatment by enabling highly personalized therapeutic strategies based on an individual's genetic, molecular, and environmental characteristics. Advances in next-generation sequencing (NGS), molecular profiling, and biomarker-driven approaches have enhanced diagnostic accuracy and optimized treatment selection. Targeted therapies, immunotherapy, and liquid biopsy techniques have significantly improved patient outcomes while minimizing adverse effects compared to conventional treatments. Despite these advancements, challenges such as tumor heterogeneity, treatment resistance, high costs, and limited accessibility continue to hinder widespread clinical adoption. While tumour heterogeneity presents a major obstacle in cancer treatment, the challenge is further compounded by the complexity of the tumour microenvironment, where dynamic interactions between cancer cells and surrounding stromal components drive disease progression. Additionally, ethical concerns regarding genetic data privacy and disparities in access to precision oncology require further attention. This review highlights the transformative impact of precision medicine in oncology, emphasizing its benefits, limitations, and the need for continued research. Future advancements in artificial intelligence, multi-omics integration, and adaptive clinical trial designs will be critical in overcoming current challenges and expanding precision medicine's applicability across diverse cancer types. With ongoing innovations, precision oncology has the potential to redefine cancer care, making tailored treatments more accessible, effective, and widely implementable.
Indexed as
Identifiers
40488843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.